Biogen (BIIB) PT Raised to $455 at Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $248.93 -0.03%
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Guggenheim analyst Yatin Suneja raised the price target on Biogen (NASDAQ: BIIB) to $455.00 (from $325.00) while maintaining a Buy rating.
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $300 at Guggenheim
- ONEOK Inc (OKE) PT Raised to $101 at Mizuho
- Shopify (SHOP) PT Lowered to $180 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
